Final results of the Royal College of Radiologists' trial comparing two different radiotherapy schedules in the treatment of cerebral metastases

Between February 1990 and February 1993, 25 centres in the UK recruited 544 patients into a prospective randomized trial comparing two whole-brain radiotherapy regimens (30 Gy in ten fractions over 2 weeks versus 12 Gy in two fractions on consecutive days) for the treatment of patients with symptoma...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical oncology (Royal College of Radiologists (Great Britain)) 1996, Vol.8 (5), p.308-315
Hauptverfasser: Priestman, T.J., Dunn, J., Brada, M., Rampling, R., Baker, P.G.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 315
container_issue 5
container_start_page 308
container_title Clinical oncology (Royal College of Radiologists (Great Britain))
container_volume 8
creator Priestman, T.J.
Dunn, J.
Brada, M.
Rampling, R.
Baker, P.G.
description Between February 1990 and February 1993, 25 centres in the UK recruited 544 patients into a prospective randomized trial comparing two whole-brain radiotherapy regimens (30 Gy in ten fractions over 2 weeks versus 12 Gy in two fractions on consecutive days) for the treatment of patients with symptomatic cerebral metastases. Of these patients 533 were eligible for analysis: 270 assigned to the two-fraction arm and 263 to the ten-fraction arm. The two groups were well balanced with respect to patient characteristics. Median survival was 77 days with two fractions (95% CI 68–89) and 84 days for the longer schedule (95% CI 67–102). Analysis of the survival curves showed a marginal advantage for ten fractions ( P = 0.04). Performance status ( P = 0.0001), site of primary tumour ( P = 0.006), dose of dexamethasone ( P = 0.004), age ( P = 0.04) and randomization treatment ( P = 0.03) were independant factors associated with survival. The classification of patients into good or poor risk groups based on these factors, excluding treatment, showed highly significant differences in survival ( P < 0.0001). Predictive models suggested that any benefit attributable to the longer radiotherapy schedule was confined to those in a good prognostic group (these patients formed 22% of the study population). Radiation related side effects, other than alopecia, were seen in 12% of patients receiving two fractions and 8% of those given ten fractions. The short survival of many patients hampered the assessment of response, but overall responses were seen in 39% of those given two fractions and 44% of patients receiving ten fractions. These results suggest that any increase in survival due to longer radiotherapy treatment is confined to good prognosis patients, but, for the majority, there is no advantage and the value of radiotherapy for these patients relates purely to the possibility of control or relief of distressing symptoms.
doi_str_mv 10.1016/S0936-6555(05)80717-4
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78556640</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0936655505807174</els_id><sourcerecordid>78556640</sourcerecordid><originalsourceid>FETCH-LOGICAL-c304t-6a48b2b5dafa1781caf5181e25f1a7f0bc144d3dd9856f8233e5233b88d817df3</originalsourceid><addsrcrecordid>eNqFkdFqFDEUhoModVt9hEIuROvF1GQmmclcFVmsCoVCq9chk5xsI5nJmmSUfQsfuZndZW-FkMA53_lP-H-ELim5poS2nx5J37RVyzm_IvyjIB3tKvYCrShrmqruBX2JVifkNTpP6RchpBaiP0Nnom8Y4WSF_t26SXkcIc0-Jxwszk-AH8KuFNfBe9jAUnxQxgUfNi7l9AHn6Epbh3Grops2OP8N2DhrIcKUcVzYohLVdoeTfgIze0jYTXvpHEHlceGKrC4TQyxaI2SVyoH0Br2yyid4e3wv0M_bLz_W36q7-6_f15_vKt0QlqtWMTHUAzfKKtoJqpXlVFCouaWqs2TQlDHTGNML3lpRNw3wcg1CGEE7Y5sL9P6gu43h9wwpy9ElDd6rCcKcZCc4b1tGCsgPoI4hpQhWbqMbVdxJSuSShNwnIRebJeFyn4RkZe7yuGAeRjCnqaP1pf_u2FdJK2-jmrRLJ6xmXVfiKtjNAYNixh8HUSbtYNJgXASdpQnuPx95BoYuqDY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78556640</pqid></control><display><type>article</type><title>Final results of the Royal College of Radiologists' trial comparing two different radiotherapy schedules in the treatment of cerebral metastases</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Priestman, T.J. ; Dunn, J. ; Brada, M. ; Rampling, R. ; Baker, P.G.</creator><creatorcontrib>Priestman, T.J. ; Dunn, J. ; Brada, M. ; Rampling, R. ; Baker, P.G.</creatorcontrib><description>Between February 1990 and February 1993, 25 centres in the UK recruited 544 patients into a prospective randomized trial comparing two whole-brain radiotherapy regimens (30 Gy in ten fractions over 2 weeks versus 12 Gy in two fractions on consecutive days) for the treatment of patients with symptomatic cerebral metastases. Of these patients 533 were eligible for analysis: 270 assigned to the two-fraction arm and 263 to the ten-fraction arm. The two groups were well balanced with respect to patient characteristics. Median survival was 77 days with two fractions (95% CI 68–89) and 84 days for the longer schedule (95% CI 67–102). Analysis of the survival curves showed a marginal advantage for ten fractions ( P = 0.04). Performance status ( P = 0.0001), site of primary tumour ( P = 0.006), dose of dexamethasone ( P = 0.004), age ( P = 0.04) and randomization treatment ( P = 0.03) were independant factors associated with survival. The classification of patients into good or poor risk groups based on these factors, excluding treatment, showed highly significant differences in survival ( P &lt; 0.0001). Predictive models suggested that any benefit attributable to the longer radiotherapy schedule was confined to those in a good prognostic group (these patients formed 22% of the study population). Radiation related side effects, other than alopecia, were seen in 12% of patients receiving two fractions and 8% of those given ten fractions. The short survival of many patients hampered the assessment of response, but overall responses were seen in 39% of those given two fractions and 44% of patients receiving ten fractions. These results suggest that any increase in survival due to longer radiotherapy treatment is confined to good prognosis patients, but, for the majority, there is no advantage and the value of radiotherapy for these patients relates purely to the possibility of control or relief of distressing symptoms.</description><identifier>ISSN: 0936-6555</identifier><identifier>EISSN: 1433-2981</identifier><identifier>DOI: 10.1016/S0936-6555(05)80717-4</identifier><identifier>PMID: 8934050</identifier><language>eng</language><publisher>Amsterdam: Elsevier Ltd</publisher><subject>Biological and medical sciences ; Brain Neoplasms - mortality ; Brain Neoplasms - radiotherapy ; Brain Neoplasms - secondary ; Cerebral metastases ; Female ; Fractionation ; Humans ; Male ; Medical sciences ; Middle Aged ; Neurology ; Palliative Care ; Proportional Hazards Models ; Radiotherapy ; Radiotherapy Dosage ; Risk Factors ; Survival Analysis ; Survival Rate ; Time Factors ; Tumors of the nervous system. Phacomatoses</subject><ispartof>Clinical oncology (Royal College of Radiologists (Great Britain)), 1996, Vol.8 (5), p.308-315</ispartof><rights>1996 The Royal College of Radiologists</rights><rights>1997 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c304t-6a48b2b5dafa1781caf5181e25f1a7f0bc144d3dd9856f8233e5233b88d817df3</citedby><cites>FETCH-LOGICAL-c304t-6a48b2b5dafa1781caf5181e25f1a7f0bc144d3dd9856f8233e5233b88d817df3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0936655505807174$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>309,310,314,776,780,785,786,3537,4010,4036,4037,23909,23910,25118,27900,27901,27902,65534</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2477002$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8934050$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Priestman, T.J.</creatorcontrib><creatorcontrib>Dunn, J.</creatorcontrib><creatorcontrib>Brada, M.</creatorcontrib><creatorcontrib>Rampling, R.</creatorcontrib><creatorcontrib>Baker, P.G.</creatorcontrib><title>Final results of the Royal College of Radiologists' trial comparing two different radiotherapy schedules in the treatment of cerebral metastases</title><title>Clinical oncology (Royal College of Radiologists (Great Britain))</title><addtitle>Clin Oncol (R Coll Radiol)</addtitle><description>Between February 1990 and February 1993, 25 centres in the UK recruited 544 patients into a prospective randomized trial comparing two whole-brain radiotherapy regimens (30 Gy in ten fractions over 2 weeks versus 12 Gy in two fractions on consecutive days) for the treatment of patients with symptomatic cerebral metastases. Of these patients 533 were eligible for analysis: 270 assigned to the two-fraction arm and 263 to the ten-fraction arm. The two groups were well balanced with respect to patient characteristics. Median survival was 77 days with two fractions (95% CI 68–89) and 84 days for the longer schedule (95% CI 67–102). Analysis of the survival curves showed a marginal advantage for ten fractions ( P = 0.04). Performance status ( P = 0.0001), site of primary tumour ( P = 0.006), dose of dexamethasone ( P = 0.004), age ( P = 0.04) and randomization treatment ( P = 0.03) were independant factors associated with survival. The classification of patients into good or poor risk groups based on these factors, excluding treatment, showed highly significant differences in survival ( P &lt; 0.0001). Predictive models suggested that any benefit attributable to the longer radiotherapy schedule was confined to those in a good prognostic group (these patients formed 22% of the study population). Radiation related side effects, other than alopecia, were seen in 12% of patients receiving two fractions and 8% of those given ten fractions. The short survival of many patients hampered the assessment of response, but overall responses were seen in 39% of those given two fractions and 44% of patients receiving ten fractions. These results suggest that any increase in survival due to longer radiotherapy treatment is confined to good prognosis patients, but, for the majority, there is no advantage and the value of radiotherapy for these patients relates purely to the possibility of control or relief of distressing symptoms.</description><subject>Biological and medical sciences</subject><subject>Brain Neoplasms - mortality</subject><subject>Brain Neoplasms - radiotherapy</subject><subject>Brain Neoplasms - secondary</subject><subject>Cerebral metastases</subject><subject>Female</subject><subject>Fractionation</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neurology</subject><subject>Palliative Care</subject><subject>Proportional Hazards Models</subject><subject>Radiotherapy</subject><subject>Radiotherapy Dosage</subject><subject>Risk Factors</subject><subject>Survival Analysis</subject><subject>Survival Rate</subject><subject>Time Factors</subject><subject>Tumors of the nervous system. Phacomatoses</subject><issn>0936-6555</issn><issn>1433-2981</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkdFqFDEUhoModVt9hEIuROvF1GQmmclcFVmsCoVCq9chk5xsI5nJmmSUfQsfuZndZW-FkMA53_lP-H-ELim5poS2nx5J37RVyzm_IvyjIB3tKvYCrShrmqruBX2JVifkNTpP6RchpBaiP0Nnom8Y4WSF_t26SXkcIc0-Jxwszk-AH8KuFNfBe9jAUnxQxgUfNi7l9AHn6Epbh3Grops2OP8N2DhrIcKUcVzYohLVdoeTfgIze0jYTXvpHEHlceGKrC4TQyxaI2SVyoH0Br2yyid4e3wv0M_bLz_W36q7-6_f15_vKt0QlqtWMTHUAzfKKtoJqpXlVFCouaWqs2TQlDHTGNML3lpRNw3wcg1CGEE7Y5sL9P6gu43h9wwpy9ElDd6rCcKcZCc4b1tGCsgPoI4hpQhWbqMbVdxJSuSShNwnIRebJeFyn4RkZe7yuGAeRjCnqaP1pf_u2FdJK2-jmrRLJ6xmXVfiKtjNAYNixh8HUSbtYNJgXASdpQnuPx95BoYuqDY</recordid><startdate>1996</startdate><enddate>1996</enddate><creator>Priestman, T.J.</creator><creator>Dunn, J.</creator><creator>Brada, M.</creator><creator>Rampling, R.</creator><creator>Baker, P.G.</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>1996</creationdate><title>Final results of the Royal College of Radiologists' trial comparing two different radiotherapy schedules in the treatment of cerebral metastases</title><author>Priestman, T.J. ; Dunn, J. ; Brada, M. ; Rampling, R. ; Baker, P.G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c304t-6a48b2b5dafa1781caf5181e25f1a7f0bc144d3dd9856f8233e5233b88d817df3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Biological and medical sciences</topic><topic>Brain Neoplasms - mortality</topic><topic>Brain Neoplasms - radiotherapy</topic><topic>Brain Neoplasms - secondary</topic><topic>Cerebral metastases</topic><topic>Female</topic><topic>Fractionation</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neurology</topic><topic>Palliative Care</topic><topic>Proportional Hazards Models</topic><topic>Radiotherapy</topic><topic>Radiotherapy Dosage</topic><topic>Risk Factors</topic><topic>Survival Analysis</topic><topic>Survival Rate</topic><topic>Time Factors</topic><topic>Tumors of the nervous system. Phacomatoses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Priestman, T.J.</creatorcontrib><creatorcontrib>Dunn, J.</creatorcontrib><creatorcontrib>Brada, M.</creatorcontrib><creatorcontrib>Rampling, R.</creatorcontrib><creatorcontrib>Baker, P.G.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical oncology (Royal College of Radiologists (Great Britain))</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Priestman, T.J.</au><au>Dunn, J.</au><au>Brada, M.</au><au>Rampling, R.</au><au>Baker, P.G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Final results of the Royal College of Radiologists' trial comparing two different radiotherapy schedules in the treatment of cerebral metastases</atitle><jtitle>Clinical oncology (Royal College of Radiologists (Great Britain))</jtitle><addtitle>Clin Oncol (R Coll Radiol)</addtitle><date>1996</date><risdate>1996</risdate><volume>8</volume><issue>5</issue><spage>308</spage><epage>315</epage><pages>308-315</pages><issn>0936-6555</issn><eissn>1433-2981</eissn><abstract>Between February 1990 and February 1993, 25 centres in the UK recruited 544 patients into a prospective randomized trial comparing two whole-brain radiotherapy regimens (30 Gy in ten fractions over 2 weeks versus 12 Gy in two fractions on consecutive days) for the treatment of patients with symptomatic cerebral metastases. Of these patients 533 were eligible for analysis: 270 assigned to the two-fraction arm and 263 to the ten-fraction arm. The two groups were well balanced with respect to patient characteristics. Median survival was 77 days with two fractions (95% CI 68–89) and 84 days for the longer schedule (95% CI 67–102). Analysis of the survival curves showed a marginal advantage for ten fractions ( P = 0.04). Performance status ( P = 0.0001), site of primary tumour ( P = 0.006), dose of dexamethasone ( P = 0.004), age ( P = 0.04) and randomization treatment ( P = 0.03) were independant factors associated with survival. The classification of patients into good or poor risk groups based on these factors, excluding treatment, showed highly significant differences in survival ( P &lt; 0.0001). Predictive models suggested that any benefit attributable to the longer radiotherapy schedule was confined to those in a good prognostic group (these patients formed 22% of the study population). Radiation related side effects, other than alopecia, were seen in 12% of patients receiving two fractions and 8% of those given ten fractions. The short survival of many patients hampered the assessment of response, but overall responses were seen in 39% of those given two fractions and 44% of patients receiving ten fractions. These results suggest that any increase in survival due to longer radiotherapy treatment is confined to good prognosis patients, but, for the majority, there is no advantage and the value of radiotherapy for these patients relates purely to the possibility of control or relief of distressing symptoms.</abstract><cop>Amsterdam</cop><pub>Elsevier Ltd</pub><pmid>8934050</pmid><doi>10.1016/S0936-6555(05)80717-4</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0936-6555
ispartof Clinical oncology (Royal College of Radiologists (Great Britain)), 1996, Vol.8 (5), p.308-315
issn 0936-6555
1433-2981
language eng
recordid cdi_proquest_miscellaneous_78556640
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Biological and medical sciences
Brain Neoplasms - mortality
Brain Neoplasms - radiotherapy
Brain Neoplasms - secondary
Cerebral metastases
Female
Fractionation
Humans
Male
Medical sciences
Middle Aged
Neurology
Palliative Care
Proportional Hazards Models
Radiotherapy
Radiotherapy Dosage
Risk Factors
Survival Analysis
Survival Rate
Time Factors
Tumors of the nervous system. Phacomatoses
title Final results of the Royal College of Radiologists' trial comparing two different radiotherapy schedules in the treatment of cerebral metastases
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-18T22%3A56%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Final%20results%20of%20the%20Royal%20College%20of%20Radiologists'%20trial%20comparing%20two%20different%20radiotherapy%20schedules%20in%20the%20treatment%20of%20cerebral%20metastases&rft.jtitle=Clinical%20oncology%20(Royal%20College%20of%20Radiologists%20(Great%20Britain))&rft.au=Priestman,%20T.J.&rft.date=1996&rft.volume=8&rft.issue=5&rft.spage=308&rft.epage=315&rft.pages=308-315&rft.issn=0936-6555&rft.eissn=1433-2981&rft_id=info:doi/10.1016/S0936-6555(05)80717-4&rft_dat=%3Cproquest_cross%3E78556640%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=78556640&rft_id=info:pmid/8934050&rft_els_id=S0936655505807174&rfr_iscdi=true